CandeSpartan Study : Candesartan Spanish Response-prediction and Tolerability study in migraine
Garcia Azorin, David (Hospital Clínico Universitario de Valladolid)
Martínez-Badillo, Cristina (Junta de Castilla y Leon)
Camiña Muñiz, Javier (Clinica Rotger Quironsalud)
Gago-Veiga, Ana Beatriz (Hospital Universitario de la Princesa (Madrid))
Morollón Sánchez-Mateos, Noemí (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
González-Quintanilla, Vicente (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Porta-Etessam, Jesús (Hospital Clínico San Carlos (Madrid))
Sierra-Mencía, Alvaro (Universidad de Valladolid)
González-García, Nuria (Hospital Clínico San Carlos (Madrid))
González-Osorio, Yésica (Universidad de Valladolid)
Polanco Fernández, Marcos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Recio-García, Andrea (Universidad de Valladolid)
Belvís, Roberto (Institut de Recerca Sant Pau)
Guerrero-Peral, Angel Luis (Hospital Clínico Universitario de Valladolid)
Universitat Autònoma de Barcelona

Data:	2024
Resum:	Effectiveness of candesartan in migraine prevention is supported by two randomized controlled trials. We aimed to assess the effectiveness, tolerability, and response predictors of candesartan in the preventive treatment of migraine. Observational, multicenter, prospective cohort study. The 50%, 75% and 30% responder rates, between weeks 8-12 and 20-24, were compared with the baseline. Treatment emergent adverse effects were systematically evaluated. Response predictors were estimated by multivariate regression models. Eighty-six patients were included, 79. 1% females, aged 39. 5 (inter-quartile range [IQR] 26. 3-50. 3), with chronic migraine (43. 0%), medication overuse headache (55. 8%) and a median of two (inter-quartile range: 0. 75-3) prior preventive treatments. At baseline patients had 14 (10-24) headache and 8 (5-11) migraine days per month. The 30%, 50% and 75% responder rates were 40%, 34. 9% and 15. 1% between weeks 8-12, and 48. 8%, 36%, and 18. 6% between weeks 20-24. Adverse effects were reported by 30 (34. 9%) and 13 (15. 1%) patients between weeks 0-12 and 12-24, leading to discontinuation in 15 (17. 4%) patients. Chronic migraine, depression, headache days per month, medication overuse headache, and daily headache at baseline predicted the response between weeks 20-24. Candesartan effectiveness and tolerability in migraine prevention was in line with the clinical trials' efficacy. The study protocol is registered in ClinicalTrials. gov (NCT04138316).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Angiotensin II type 1 receptor blockers ; Headache disorders ; Hypertension ; Migraine ; Primary
Publicat a:	Cephalalgia, Vol. 44 Núm. 4 (april 2024) , ISSN 1468-2982

DOI: 10.1177/03331024241248833
PMID: 38663908

10 p, 1.0 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats